A PHASE 1 STUDY EVALUATING COM701 IN PATIENTS WITH ADVANCED SOLID TUMORS


South Texas Accelerated Research Therapeutics (START), San Antonio, TX; West Cancer Center, Memphis, TN; Massachusetts General Hospital, Boston, MA; University of Pittsburgh Medical Center, Pittsburgh, PA; Compugen USA Inc., South San Francisco, CA; and Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN

BACKGROUND

• There is a high unmet medical need for the treatment of patients who are refractory to or relapse following treatment with checkpoint inhibitors
• Newer checkpoint therapies with novel mechanisms of action that can activate T cells and demonstrate antitumor activity in this pre-IRI pt population are urgently needed

COM701 is a novel first-in-class humanized IgG4 monoclonal antibody that binds with high affinity to poliovirus receptor related immunoglobulin domain containing (PVRIG) blocking its interaction with its ligand, PVR. L2
• Inhibition of PVRIG leads to enhanced activation of T and NK cells, and PVRIG results in tumor growth inhibition in mouse tumor models

We hypothesize that COM701 will be safe and tolerable and demonstrate antitumor activity in pts with R/R solid tumors

METHODS

• NCT03667716 is an ongoing open-label first-in-human phase 1 study in pts with R/R solid tumors
• We report on the initial part of this study evaluating the safety and tolerability of escalating doses of COM701 monotherapy IV Q3 weekly

EXPLORATORY OUTCOME MEASURES

• To evaluate preliminary antitumor activity of COM701 as monotherapy
• To assess any association of DNAM axis members with clinical outcome
• To explore evidence of COM701-mediated PD effect in blood as monotherapy as well as in combination with Opdivo

KEY INCLUSION CRITERIA

• Age ≥18 yrs
• Histologically or cytologically confirmed, locally advanced or metastatic solid malignancy and has exhausted all the available standard therapy or is not a candidate for the available standard therapy
• ECOG performance status 0–1
• Prior anti-PD-1, anti-PD-L1, anti-CTLA-4,OX-40, CD137 permissible
• Adequate hematological, hepatic and renal function

KEY EXCLUSION CRITERIA

• As of the date of this presentation the patient dose cohort has been filled
• No dose-limiting toxicities have been observed in the 6th patient cohort and earlier dose cohorts
• Assessment is ongoing for the next higher dose cohort

ACCURAL INFORMATION

• As of the date of this presentation the 6th patient dose cohort has been filled
• No dose-limiting toxicities have been observed in the 6th patient cohort and earlier dose cohorts
• Assessment is ongoing for the next higher dose cohort

ACKNOWLEDGMENT

• We thank the patients for participating in this clinical trial and their families
• The investigators and clinical trial sites
• Study NCT03667716 is in collaboration with Bristol Myers Squibb

REFERENCE

1. Ganguly and Parrill, Johns Hopkins Univ. MC38 model

Study sponsored by Compugen Ltd. For more information: www.cgen.com